We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Harmonizing U.S., EU Orphan Protocol Guidance Could Speed Access to Therapies
Harmonizing U.S., EU Orphan Protocol Guidance Could Speed Access to Therapies
May 10, 2012
To help drugmakers speed new therapies to patients with rare diseases, U.S. and EU regulators should harmonize their philosophies around orphan drug development and generate common guidance on trial requirements, experts say.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor